Barclays Cuts Abbott Laboratories (NYSE:ABT) Price Target to $142.00

Abbott Laboratories (NYSE:ABT) had its price objective trimmed by Barclays from $169.00 to $142.00 in a report published on Monday morning, MarketBeat Ratings reports. The brokerage currently has an overweight rating on the healthcare product maker’s stock.

Other equities analysts also recently issued reports about the stock. Piper Sandler lowered their target price on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. BTIG Research decreased their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Leerink Partners cut their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. The Goldman Sachs Group decreased their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Finally, Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $137.05.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $108.18 on Monday. The firm has a market capitalization of $188.11 billion, a price-to-earnings ratio of 29.08, a price-to-earnings-growth ratio of 1.73 and a beta of 0.75. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The business’s 50 day simple moving average is $121.62 and its 200-day simple moving average is $127.11. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.Abbott Laboratories’s revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Hedge Funds Weigh In On Abbott Laboratories

Hedge funds and other institutional investors have recently bought and sold shares of the stock. IMG Wealth Management Inc. boosted its position in Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares during the last quarter. Harbor Capital Advisors Inc. purchased a new position in Abbott Laboratories in the fourth quarter valued at about $27,000. Cloud Capital Management LLC purchased a new position in Abbott Laboratories in the third quarter valued at about $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories during the 3rd quarter worth approximately $31,000. Finally, Anfield Capital Management LLC raised its position in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.